CCM
AMAM

CAAS Capital Management’s Ambrx Biopharma Inc AMAM Stock Holding History

CAAS Capital Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,068
Closed -$118K – 1008
2021
Q4 		$118K Sell
13,068
-26,932
-67% -$301K ﹤0.01% 706
2021
Q3 		$540K Hold
40,000
– – 0.01% 600
2021
Q2 		$784K Buy
+40,000
New +$682K 0.01% 646

Other funds holding AMAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CAAS Capital Management's AMAM Position: Q1 2022 in Review

CAAS Capital Management sold out of Ambrx Biopharma Inc (AMAM) in Q1 2022, closing a stake of 13,068 shares — an estimated $118K sold.

CAAS Capital Management first reported a position in AMAM in Q2 2021 and held it in 3 quarters. The position peaked at $784K in Q2 2021. 14 funds tracked by Wall St. Rank hold AMAM as of Q1 2022.

  • CAAS Capital Management reported no remaining Ambrx Biopharma Inc position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 13,068 Ambrx Biopharma Inc shares in Q1 2022, an estimated $118K.
  • CAAS Capital Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 3 quarters.
  • CAAS Capital Management's Ambrx Biopharma Inc position peaked at $784K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.